United States Solid Tumors Drugs Market Report 2017

Name: United States Solid Tumors Drugs Market Report 2017
Brand: QYResearch
SKU: U873B50F415EN
Price: 3800 USD
Availability: InStock

February 2017 | 107 pages | ID: U873B50F415EN
QYResearch

US$ 3,800.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer

Checkout Later

Need Help? Ask a Question

Notes:
Sales, means the sales volume of Solid Tumors Drugs

Revenue, means the sales value of Solid Tumors Drugs

This report studies sales (consumption) of Solid Tumors Drugs in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering

Hoffmann-La Roche
Novartis
Celgene
Johnson & Johnson
Pfizer
BMS
AbbVie
AbGenomics
ADC Therapeutics
TG Therapeutics
Polaris Pharmaceuticals
Immunogen
CTI BioPharma
Chugai Pharmaceutical
NewLink Genetics

Market Segment by States, covering

California
Texas
New York
Florida
Illinois

Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into

Type I
Type II

Split by applications, this report focuses on sales, market share and growth rate of Solid Tumors Drugs in each application, can be divided into

Application 1
Application 2

United States Solid Tumors Drugs Market Report 2017

1 SOLID TUMORS DRUGS OVERVIEW

1.1 Product Overview and Scope of Solid Tumors Drugs
1.2 Classification of Solid Tumors Drugs
  1.2.1 Type I
  1.2.2 Type II
1.3 Application of Solid Tumors Drugs
  1.3.1 Application
  1.3.2 Application
1.4 United States Market Size Sales (Volume) and Revenue (Value) of Solid Tumors Drugs (2012-2022)
  1.4.1 United States Solid Tumors Drugs Sales and Growth Rate (2012-2022)
  1.4.2 United States Solid Tumors Drugs Revenue and Growth Rate (2012-2022)

2 UNITED STATES SOLID TUMORS DRUGS COMPETITION BY MANUFACTURERS

2.1 United States Solid Tumors Drugs Sales and Market Share of Key Manufacturers (2015 and 2016)
2.2 United States Solid Tumors Drugs Revenue and Share by Manufactures (2015 and 2016)
2.3 United States Solid Tumors Drugs Average Price by Manufactures (2015 and 2016)
2.4 Solid Tumors Drugs Market Competitive Situation and Trends
  2.4.1 Solid Tumors Drugs Market Concentration Rate
  2.4.2 Solid Tumors Drugs Market Share of Top 3 and Top 5 Manufacturers
  2.4.3 Mergers & Acquisitions, Expansion

3 UNITED STATES SOLID TUMORS DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY STATES (2012-2017)

3.1 United States Solid Tumors Drugs Sales and Market Share by States (2012-2017)
3.2 United States Solid Tumors Drugs Revenue and Market Share by States (2012-2017)
3.3 United States Solid Tumors Drugs Price by States (2012-2017)

4 UNITED STATES SOLID TUMORS DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (2012-2017)

4.1 United States Solid Tumors Drugs Sales and Market Share by Type (2012-2017)
4.2 United States Solid Tumors Drugs Revenue and Market Share by Type (2012-2017)
4.3 United States Solid Tumors Drugs Price by Type (2012-2017)
4.4 United States Solid Tumors Drugs Sales Growth Rate by Type (2012-2017)

5 UNITED STATES SOLID TUMORS DRUGS SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Solid Tumors Drugs Sales and Market Share by Application (2012-2017)
5.2 United States Solid Tumors Drugs Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES SOLID TUMORS DRUGS MANUFACTURERS PROFILES/ANALYSIS

6.1 Hoffmann-La Roche
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Solid Tumors Drugs Product Type, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Hoffmann-La Roche Solid Tumors Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Novartis
  6.2.2 Solid Tumors Drugs Product Type, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Novartis Solid Tumors Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Celgene
  6.3.2 Solid Tumors Drugs Product Type, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Celgene Solid Tumors Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Johnson & Johnson
  6.4.2 Solid Tumors Drugs Product Type, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Johnson & Johnson Solid Tumors Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Pfizer
  6.5.2 Solid Tumors Drugs Product Type, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Pfizer Solid Tumors Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 BMS
  6.6.2 Solid Tumors Drugs Product Type, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 BMS Solid Tumors Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 AbbVie
  6.7.2 Solid Tumors Drugs Product Type, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 AbbVie Solid Tumors Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 AbGenomics
  6.8.2 Solid Tumors Drugs Product Type, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 AbGenomics Solid Tumors Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 ADC Therapeutics
  6.9.2 Solid Tumors Drugs Product Type, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 ADC Therapeutics Solid Tumors Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 TG Therapeutics
  6.10.2 Solid Tumors Drugs Product Type, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 TG Therapeutics Solid Tumors Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview
6.11 Polaris Pharmaceuticals
6.12 Immunogen
6.13 CTI BioPharma
6.14 Chugai Pharmaceutical
6.15 NewLink Genetics

7 SOLID TUMORS DRUGS MANUFACTURING COST ANALYSIS

7.1 Solid Tumors Drugs Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Solid Tumors Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Solid Tumors Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Solid Tumors Drugs Major Manufacturers in 2015
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES SOLID TUMORS DRUGS MARKET FORECAST (2017-2022)

11.1 United States Solid Tumors Drugs Sales, Revenue Forecast (2017-2022)
11.2 United States Solid Tumors Drugs Sales Forecast by Type (2017-2022)
11.3 United States Solid Tumors Drugs Sales Forecast by Application (2017-2022)
11.4 Solid Tumors Drugs Price Forecast (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

Methodology
Analyst Introduction
Data Source

The report requires updating with new data and is sent in 2-3 business days after order is placed.

LIST OF TABLES AND FIGURES

Figure Picture of Solid Tumors Drugs
Table Classification of Solid Tumors Drugs
Figure United States Sales Market Share of Solid Tumors Drugs by Type in 2015
Table Application of Solid Tumors Drugs
Figure United States Sales Market Share of Solid Tumors Drugs by Application in 2015
Figure United States Solid Tumors Drugs Sales and Growth Rate (2012-2022)
Figure United States Solid Tumors Drugs Revenue and Growth Rate (2012-2022)
Table United States Solid Tumors Drugs Sales of Key Manufacturers (2015 and 2016)
Table United States Solid Tumors Drugs Sales Share by Manufacturers (2015 and 2016)
Figure 2015 Solid Tumors Drugs Sales Share by Manufacturers
Figure 2016 Solid Tumors Drugs Sales Share by Manufacturers
Table United States Solid Tumors Drugs Revenue by Manufacturers (2015 and 2016)
Table United States Solid Tumors Drugs Revenue Share by Manufacturers (2015 and 2016)
Table 2015 United States Solid Tumors Drugs Revenue Share by Manufacturers
Table 2016 United States Solid Tumors Drugs Revenue Share by Manufacturers
Table United States Market Solid Tumors Drugs Average Price of Key Manufacturers (2015 and 2016)
Figure United States Market Solid Tumors Drugs Average Price of Key Manufacturers in 2015
Figure Solid Tumors Drugs Market Share of Top 3 Manufacturers
Figure Solid Tumors Drugs Market Share of Top 5 Manufacturers
Table United States Solid Tumors Drugs Sales by States (2012-2017)
Table United States Solid Tumors Drugs Sales Share by States (2012-2017)
Figure United States Solid Tumors Drugs Sales Market Share by States in 2015
Table United States Solid Tumors Drugs Revenue and Market Share by States (2012-2017)
Table United States Solid Tumors Drugs Revenue Share by States (2012-2017)
Figure Revenue Market Share of Solid Tumors Drugs by States (2012-2017)
Table United States Solid Tumors Drugs Price by States (2012-2017)
Table United States Solid Tumors Drugs Sales by Type (2012-2017)
Table United States Solid Tumors Drugs Sales Share by Type (2012-2017)
Figure United States Solid Tumors Drugs Sales Market Share by Type in 2015
Table United States Solid Tumors Drugs Revenue and Market Share by Type (2012-2017)
Table United States Solid Tumors Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Solid Tumors Drugs by Type (2012-2017)
Table United States Solid Tumors Drugs Price by Type (2012-2017)
Figure United States Solid Tumors Drugs Sales Growth Rate by Type (2012-2017)
Table United States Solid Tumors Drugs Sales by Application (2012-2017)
Table United States Solid Tumors Drugs Sales Market Share by Application (2012-2017)
Figure United States Solid Tumors Drugs Sales Market Share by Application in 2015
Table United States Solid Tumors Drugs Sales Growth Rate by Application (2012-2017)
Figure United States Solid Tumors Drugs Sales Growth Rate by Application (2012-2017)
Table Hoffmann-La Roche Basic Information List
Table Hoffmann-La Roche Solid Tumors Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Figure Hoffmann-La Roche Solid Tumors Drugs Sales Market Share (2012-2017)
Table Novartis Basic Information List
Table Novartis Solid Tumors Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Table Novartis Solid Tumors Drugs Sales Market Share (2012-2017)
Table Celgene Basic Information List
Table Celgene Solid Tumors Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Table Celgene Solid Tumors Drugs Sales Market Share (2012-2017)
Table Johnson & Johnson Basic Information List
Table Johnson & Johnson Solid Tumors Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Table Johnson & Johnson Solid Tumors Drugs Sales Market Share (2012-2017)
Table Pfizer Basic Information List
Table Pfizer Solid Tumors Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Table Pfizer Solid Tumors Drugs Sales Market Share (2012-2017)
Table BMS Basic Information List
Table BMS Solid Tumors Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Table BMS Solid Tumors Drugs Sales Market Share (2012-2017)
Table AbbVie Basic Information List
Table AbbVie Solid Tumors Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Table AbbVie Solid Tumors Drugs Sales Market Share (2012-2017)
Table AbGenomics Basic Information List
Table AbGenomics Solid Tumors Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Table AbGenomics Solid Tumors Drugs Sales Market Share (2012-2017)
Table ADC Therapeutics Basic Information List
Table ADC Therapeutics Solid Tumors Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Table ADC Therapeutics Solid Tumors Drugs Sales Market Share (2012-2017)
Table TG Therapeutics Basic Information List
Table TG Therapeutics Solid Tumors Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Table TG Therapeutics Solid Tumors Drugs Sales Market Share (2012-2017)
Table Polaris Pharmaceuticals Basic Information List
Table Immunogen Basic Information List
Table CTI BioPharma Basic Information List
Table Chugai Pharmaceutical Basic Information List
Table NewLink Genetics Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Solid Tumors Drugs
Figure Manufacturing Process Analysis of Solid Tumors Drugs
Figure Solid Tumors Drugs Industrial Chain Analysis
Table Raw Materials Sources of Solid Tumors Drugs Major Manufacturers in 2015
Table Major Buyers of Solid Tumors Drugs
Table Distributors/Traders List
Figure United States Solid Tumors Drugs Production and Growth Rate Forecast (2017-2022)
Figure United States Solid Tumors Drugs Revenue and Growth Rate Forecast (2017-2022)
Table United States Solid Tumors Drugs Production Forecast by Type (2017-2022)
Table United States Solid Tumors Drugs Consumption Forecast by Application (2017-2022)
Table United States Solid Tumors Drugs Sales Forecast by States (2017-2022)
Table United States Solid Tumors Drugs Sales Share Forecast by States (2017-2022)

United States Solid Tumors Drugs Market Report 2017

More Publications

Need Help?

Ask a Question

Market Reports